Prevymis Shortage: What Providers and Prescribers Need to Know in 2026

As a transplant specialist, hematologist, oncologist, or infectious disease physician who prescribes Prevymis (letermovir), you may have encountered increasing difficulty helping your patients access this critical CMV prophylaxis medication. This article provides a clinical overview of the access landscape for Prevymis in 2026, along with practical guidance for navigating specialty pharmacy systems, insurance prior authorization, and patient assistance programs.

Current Prevymis Availability Status

Prevymis is not on the FDA's official drug shortage list as of 2026. Merck continues manufacturing letermovir in all approved formulations: 240 mg and 480 mg oral tablets, 20 mg and 120 mg oral pellet packets, and 240 mg/12 mL and 480 mg/24 mL IV injection vials. Supply chain disruptions are not the primary driver of access problems. Instead, the barriers are structural:

• Exclusive specialty pharmacy distribution model
• Insurance prior authorization requirements at most commercial and Part D plans
• Retail price of approximately $8,700+ per 30-day supply creating out-of-pocket barriers
• Expanded pediatric and renal transplant indications increasing demand since 2023

Clinical Background: Prevymis Indications and Dosing

Prevymis is FDA-approved for two indications:

1. CMV prophylaxis in HSCT recipients: Adult and pediatric patients ≥6 months of age and ≥6 kg who are CMV-seropositive (R+) recipients of allogeneic HSCT. Standard dosing: 480 mg once daily, initiated between Day 0 and Day 28 post-transplant, continued through Day 100. Extend through Day 200 in high-risk patients.
2. CMV prophylaxis in high-risk kidney transplant recipients: Adult and pediatric patients ≥12 years of age and ≥40 kg who are D+/R- kidney transplant recipients. Standard dosing: 480 mg once daily for up to 200 days post-transplant.

Cyclosporine dose adjustment: When letermovir is co-administered with cyclosporine, reduce letermovir dose to 240 mg once daily (adult and pediatric ≥12 years). Monitor cyclosporine levels closely, as letermovir inhibits OATP1B1/3-mediated hepatic uptake and increases cyclosporine exposure.

Why Prevymis Is Preferred Over Valganciclovir in Many Settings

The phase 3 trial (Limaye et al., JAMA 2023) comparing letermovir to valganciclovir in high-risk kidney transplant recipients demonstrated that letermovir was non-inferior to valganciclovir for CMV disease prevention through 1 year (10.4% vs 11.8%), with substantially fewer hematologic adverse events:

• Leukopenia or neutropenia: 26% (letermovir) vs 64% (valganciclovir)
• Discontinuation due to adverse events: 4.1% vs 13.5%
• Resistance-associated substitutions: 0% (letermovir) vs 12.1% (valganciclovir)

Additionally, letermovir dosing is independent of kidney function (no creatinine clearance-based adjustment needed for oral dosing), which simplifies management in the post-transplant period when renal function is fluctuating.

Navigating Prior Authorization for Prevymis

Most commercial insurers and Medicare Part D plans require prior authorization for Prevymis. Key documentation to include:

• Transplant type (HSCT or kidney) and date
• CMV serostatus of donor and recipient (R+ for HSCT; D+/R- for kidney)
• Prescriber specialty (must be prescribed by Infectious Disease, Hematology, Oncology, or Transplant specialist per most payer criteria)
• Duration of therapy intended (100 days for HSCT, up to 200 days for kidney transplant)
• Concomitant cyclosporine use (affects letermovir dose and some payer criteria)

Some plans (e.g., BCBS Arizona criteria reviewed February 2026) may also require documentation of failure or contraindication to a generic alternative if one is available. Since no generic letermovir exists, this requirement should not apply, but be prepared to document this explicitly if challenged.

Connecting Patients to Specialty Pharmacies

Prevymis is typically dispensed through specialty pharmacies. Your prescribing workflow should include directing patients or sending the prescription to a specialty pharmacy your program works with. National specialty pharmacies equipped to handle letermovir include Accredo (Express Scripts), CVS Specialty, Walgreens Specialty, and Optum Specialty.

For patients who need help locating which pharmacies near them can fill a Prevymis prescription, medfinder for providers is a resource that contacts pharmacies by phone on behalf of the patient and reports back which ones have it in stock — a practical tool for your transplant team to share with patients at discharge.

Patient Assistance Resources

For uninsured or underinsured patients, the Merck Access Program provides financial assistance and pharmacy navigation support. Commercially insured patients can pay as little as $15 per prescription through Merck's savings card program (up to 8 qualifying prescriptions). Contact the program at 1-855-257-3932 or refer patients to the Merck Access Program for enrollment.

Key Drug Interactions to Flag at Discharge

Given letermovir's complex pharmacokinetic profile as a CYP3A moderate inhibitor and CYP2C8 inhibitor, ensure patients are counseled on and medications reviewed for:

• Contraindicated: Pimozide (QT prolongation risk), ergot alkaloids (ergotism risk), pitavastatin/simvastatin when co-administered with cyclosporine (rhabdomyolysis risk)
• Monitor closely: Tacrolimus, sirolimus (OATP1B1/3 substrates), warfarin, amiodarone, antiepileptics (phenytoin, carbamazepine — also reduce letermovir levels), voriconazole (letermovir induces voriconazole metabolism)
• Reduce letermovir levels (avoid or use with caution): Rifampin, St. John's Wort, bosentan, efavirenz, etravirine, nafcillin, modafinil

When to Consider Alternatives

If access to letermovir remains impossible despite exhausting specialty pharmacy and assistance program options, valganciclovir remains a viable alternative for most indications, with appropriate renal dose adjustment. For patients unable to tolerate either agent, consult with your institution's pharmacist and infectious disease team. For a patient-facing overview of alternatives, see: Alternatives to Prevymis.